Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Esophageal Cancer | Research

The prognostic role of pre-treatment neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy

Authors: Qirong Man, Peishun Li, Jing Fan, Sen Yang, Chao Xing, Yunling Bai, Miaomiao Hu, Baohu wang, Kaixian Zhang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Purpose

In this study, we retrospectively investigated the prognostic role of pre-treatment neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in esophageal squamous cell carcinoma patients (ESCC) treated with concurrent chemo-radiotherapy (CCRT).

Methods

We retrospectively analyzed the records of 338 patients with pathologically diagnosed esophageal squamous cell carcinoma that underwent concurrent chemo-radiotherapy from January 2013 to December 2017. Univariate and multivariate analyses were used to identify prognostic factors for progression free survival (PFS) and overall survival (OS).

Results

The result showed that the thresholds for NLR and PLR were 2.47 and 136.0 by receiver operating characteristic curve. High NLR and PLR were both associated with tumor length (P < 0.05). High NLR and PLR were significantly associated with poor PFS and OS. Multivariate analyses identified NLR, PLR and TNM stage were independent risk factors for PFS and OS.

Conclusions

We show that the pre-treatment NLR and PLR may serve as prognostic indicators for esophageal squamous cell carcinoma treated with concurrent chemo-radiotherapy.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
2.
Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383–96.CrossRefPubMed
3.
Lin Y, Totsuka Y, He Y, et al. Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013;23(4):233–42.CrossRefPubMed
4.
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of Locally Advanced Esophageal Cancer: Long-Term Follow-Up of a Prospective Randomized Trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA;1999; 281(17):1623–1627.
5.
Li C, Ni W, Wang X, Bi N, Zhang T, Xiao Z, et al. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Radiat Oncol. 2019;14(1):48–55.CrossRefPubMedPubMedCentral
6.
Zhang Y, Feng W, Gao LT, Cai XW, et al. Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma. Radiother Oncol. 2021;159:190–6.CrossRefPubMed
7.
Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomized controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRefPubMed
8.
Zou B, Pang J, Liu Y, Xu Y, Li L, Zhou L, et al. Postoperative chemoradiotherapy improves survival in patients with stage II-III esophageal squamous cell carcinoma: An analysis of clinical outcomes. Thoracic Cancer. 2016;7(5):515–21.CrossRefPubMedPubMedCentral
9.
Mjd Arnal, Arenas ÁF, Arbeloa ÁL. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015, 21:7933–7943.
10.
11.
Abdel-Latif MM, Duggan S, Reynolds JV, Kelleher D. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol. 2009;9(4):396–404.CrossRefPubMed
12.
13.
14.
Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair (Amst). 2019;83: 102673.CrossRefPubMed
15.
Kara M, Uysal S, Altinisik U, Cevizci S, Güçlü O, Dereköy FS. The pre-treatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red cell distribution width predict prognosis in patients with laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2017;274:535–42.CrossRefPubMed
16.
Wu G, Yao Y, Bai C, Zeng J, Shi D, Gu X, et al. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients]. Thorac Cancer. 2015;6:275–87.CrossRefPubMedPubMedCentral
17.
Schobert IT, Savic LJ, Chapiro J, Bousabarah K, Chen E, Laage-Gaupp F, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol. 2020;30(10):5663–73.CrossRefPubMedPubMedCentral
18.
Aqua Asif, Vinson Wai-Shun Chan, Filzah Hanis Osman, Jasmine Sze-Ern Koe, Alexander Ng, Oliver Edward Burton, et al .The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Small Renal Cell Carcinomas after Image-Guided Cryoablation or Radio-Frequency Ablation. Cancers (Basel). 2023;15(7):2187.
19.
Sciarra A, Gentilucci A, Cattarino S, Salsiccia S, Mariotti G. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Minerva Urol Nephrol. 2021;73(6):863–5.PubMed
20.
Zhao Z, Zhao X, Lu J, Xue J, Liu P, Mao H. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. Arch Gynecol Obstet. 2018;297(4):849–57.CrossRefPubMed
21.
Rashid F, Waraich N, Bhatti I, et al. A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol. 2010;8:1.CrossRefPubMedPubMedCentral
22.
Dutta S, Crumley AB, Fullarton GM, et al. Comparison of the prognostic value of tumour- and patient- related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35(8):1861–6.CrossRefPubMed
23.
Hirahara N, Matsubara T, Hayashi H, et al. Impact of inflammation-based prognostic score on survival after curative thoracoscopic esophagectomy for esophageal cancer. Eur J Surg Oncol. 2015;41(10):1308–15.CrossRefPubMed
24.
Jung J, Park SY, Park SJ, et al. Prognostic value of the neutrophil-to-lymphocyte ratio for overall and disease- free survival in patients with surgically treated esophageal squamous cell carcinoma. Tumour Biol. 2015;12:12.
25.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205–216.
26.
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.CrossRefPubMed
27.
Lan H, Zhou L, Chi D, Zhou Q, Tang X, Zhu D, et al. Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: A single institutional cohort study. Oncotarget. 2017;8:35301–10.CrossRefPubMed
28.
Sanchez‑Salcedo P, de‑Torres JP, Martinez‑Urbistondo D, Gonzalez‑Gutierrez J, Berto J, Campo A, et al. The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development. Lung Cancer, 2016;97:28–34.
29.
Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E, McDonald AC. Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis. 2012;14(10):e701-707.CrossRefPubMed
30.
Zanoni MT, Salzano G, Lambertoni A, Giovannardi M, Karligkiotis A, Battaglia P, Castelnuovo P. Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio. Head Neck. 2016;39:730.CrossRef
31.
Nakashima H, Matsuoka Y, Yoshida R, Nagata M, Hirosue A, Kawahara K, Sakata J, Arita H, Hiraki A, Nakayama H. Pre-treatment neutrophil to lymphocyte ratio predicts the chemoradiotherapy outcome and survival in patients with oral squamous cell carcinoma: A retrospective study. BMC Cancer. 2016;16:1.CrossRef
32.
Acharya S, Rai P, Hallikeri K, Anehosur V, Kale J: Preoperative platelet lymphocyte ratio is superior to neutrophil lymphocyte ratio to be used as predictive marker for lymph node metastasis in oral squamous cell carcinoma. J Investig Clin Dent.: 1, 2016.
33.
Oliveira ML, Wagner VP, Sant’ana Filho M, Carrard VC, Hugo FN, Martins MD. A 10-year analysis of the oral squamous cell carcinoma profile in patients from public health centers in Uruguay. Braz Oral Res. 2015;29:1.PubMed
34.
Xie X, Luo KJ, Hu Y, et al. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. DisEsophagus. 2016;29(1):79–85.
35.
Rassouli A, Saliba J, Castano R, Hier M, Zeitouni AG. Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma. Head Neck. 2014;37:1.
36.
Sato H, Tsubosa Y, Kawano T. Correlation between the pre-therapeutic neutrophil-to- lymphocyte ratio and the pathologic response to neo-adjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012;6(3):617–22.CrossRef
37.
Sharoiha RZ, Halazun KJ, Mirza F, et al. Elevated preoperative neutrophil: lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18(12):3362–9.CrossRef
38.
Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:58.CrossRefPubMedPubMedCentral
39.
Messager M, Neofytou K, Chaudry MA, et al. Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.Eur J Surg Onco, 2015, 1(10):1316–1323.
40.
Sabrkhany S, Grif AW, Mirjam GA. The role of blood platelets in tumor angiogenesis. Biochem Biophys Acta. 2011;1815:189.PubMed
41.
Egan K, Crowley D, Smyth P, Toole SO, Spillane C, et al. Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells. PLoS One 6, 2011.
42.
Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas. 2004;29:132.CrossRefPubMed
43.
Jain S, Harris J, Ware J: ATVB in Focus Platelets Unplugged: Focus on Platelet Biology Linking Hemostasis and Cancer. Arterioscler Thromb Vasc Biol: 2362, 2010.
44.
45.
Nieswandt BB, Echtenacher B, Wachs F, Schro J, Gessner JE, Schmidt RE, et al. Acute Systemic Reaction and Lung Alterations Induced by an Antiplatelet Integrin gpIIb/IIIa Antibody in Mice. Blood. 2019;94:684.CrossRef
46.
Hoffmann K, Dworacki G, Meidenbauer N, Johnson JT: Spontaneous Apoptosis of Circulating T Lymphocytes in Patients with Head and Neck Cancer and Its Clinical Importance. Clin Cancer Res. 1. 8: 2553, 2002.
47.
Thibodeau J, Bourgeois-Daigneault MC, Lapointe R.: Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology: 1, 2012.
Metadata
Title
The prognostic role of pre-treatment neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy
Authors
Qirong Man
Peishun Li
Jing Fan
Sen Yang
Chao Xing
Yunling Bai
Miaomiao Hu
Baohu wang
Kaixian Zhang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12242-5

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Health care seeking behaviour towards cervical cancer screening among women aged 30–49 years in Arbaminch town, Southern Ethiopia, 2023

Research

Exploration of the relationship between tumor-infiltrating lymphocyte score and histological grade in breast cancer

Research

Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC

Research

Physician-brief advice for promoting smoking cessation among cancer patients on treatment in low and middle-income countries: a scoping review

Research

UTP11 promotes the growth of hepatocellular carcinoma by enhancing the mRNA stability of Oct4

Research

Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits